Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

SABCS 2016

6 - 10 Dec 2016

Henry B. Gonzalez Convention Center, San Antonio, United States of America

SABCS 2016: Interim phase Ib/II results of pembrolizumab with eribulin for triple negative breast cancer

SABCS 2016: Interim phase Ib/II results of pembrolizumab with eribulin for triple negative breast cancer

SABCS 2016: Anti-proliferative effects of selective RARα agonist in subsets of breast cancer

SABCS 2016: Anti-proliferative effects of selective RARα agonist in subsets of breast cancer

SABCS 2016: Phase I data for antibody-drug conjugate SGN-LIV1A in patients with MBC

SABCS 2016: Phase I data for antibody-drug conjugate SGN-LIV1A in patients with MBC

SABCS 2016: Untreated effects of breast cancer care increase depression and anxiety among survivors

SABCS 2016: Untreated effects of breast cancer care increase depression and anxiety among survivors

SABCS 2016: IBM Watson For Oncology shows high degree of concordance with physician recommendations

SABCS 2016: IBM Watson For Oncology shows high degree of concordance with physician recommendations

SABCS 2016: Aromatase inhibitors associated with reduced endothelial function in postmenopausal breast cancer patients

SABCS 2016: Aromatase inhibitors associated with reduced endothelial function in postmenopausal breast cancer...

SABCS 2016: Scalp-cooling system reduced hair loss in many breast cancer patients receiving chemotherapy

SABCS 2016: Scalp-cooling system reduced hair loss in many breast cancer patients receiving chemotherapy

SABCS 2016: Menopausal symptoms may be mistaken for tamoxifen side effects

SABCS 2016: Menopausal symptoms may be mistaken for tamoxifen side effects

SABCS 2016: More complications for breast cancer patients who get radiation, implants

SABCS 2016: More complications for breast cancer patients who get radiation, implants

SABCS 2016: BELLE-3 trial meets primary endpoint of progression-free survival for breast cancer

SABCS 2016: BELLE-3 trial meets primary endpoint of progression-free survival for breast cancer

SABCS 2016: Trial of presurgery abemaciclib treatment for early-stage HR-pos/HER2-neg breast cancer met primary endpoint

SABCS 2016: Trial of presurgery abemaciclib treatment for early-stage HR-pos/HER2-neg breast cancer met primary...

SABCS 2016: Adding ibandronate to hormone therapy did not improve outcomes for postmenopausal breast cancer patients

SABCS 2016: Adding ibandronate to hormone therapy did not improve outcomes for postmenopausal breast cancer...

SABCS 2016: Adding an aromatase inhibitor to presurgery treatment for HR/HER2 positive breast cancer provided no additional benefit

SABCS 2016: Adding an aromatase inhibitor to presurgery treatment for HR/HER2 positive breast cancer provided no...

SABCS 2016 : Adding everolimus to fulvestrant improved outcomes for postmenopausal patients with HR-positive breast cancer

SABCS 2016 : Adding everolimus to fulvestrant improved outcomes for postmenopausal patients with HR-positive...

SABCS 2016: Genomic sequencing of treatment-resistant metastatic breast cancer reveals clinically relevant genetic alterations

SABCS 2016: Genomic sequencing of treatment-resistant metastatic breast cancer reveals clinically relevant genetic...

SABCS 2016: Extended letrozole therapy showed limited benefit in postmenopausal women with early-stage, HR-positive breast cancer

SABCS 2016: Extended letrozole therapy showed limited benefit in postmenopausal women with early-stage, HR...

SABCS 2016 : Adding veliparib to chemotherapy improved response rates among patients with BRCA-mutant breast cancer

SABCS 2016 : Adding veliparib to chemotherapy improved response rates among patients with BRCA-mutant breast cancer

More from ecancer